The startup operates a cancer diagnostic laboratory that provides genomic profiling for solid and hematologic cancers, utilizing next-generation sequencing technologies to deliver precise genetic insights. By partnering with laboratories, hospitals, and oncology practices, the company enhances diagnostic accuracy and treatment personalization for cancer patients.
Funding
$900K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Comprehensive genomic profiling of cancers is essential for accurate diagnosis and personalized treatment, but traditional methods can be limited by the availability of tissue samples, the invasiveness of biopsies, and the turnaround time for results. Partial results from limited testing can hinder optimal care decisions.
Solution
Genomic Testing Cooperative (GTC) provides comprehensive genomic profiling services for both solid and hematologic cancers, utilizing next-generation sequencing (NGS) of DNA and RNA to identify driver mutations, sub-clonal mutations, and other clinically relevant biomarkers. GTC's approach includes comprehensive analysis of both DNA and RNA, offering a more complete understanding of the tumor's molecular signature compared to DNA-only testing. The company's liquid biopsy options, performed on cell-free DNA (cfDNA) and cell-free RNA (cfRNA), offer a non-invasive alternative to traditional bone marrow biopsies, reducing patient discomfort and enabling frequent monitoring. GTC leverages AI and machine learning to interpret complex genomic data, providing clinicians with actionable insights for diagnosis, prognosis, and treatment selection, including targeted therapies, immunotherapies, and clinical trial options.
Target Audience
GTC primarily serves pathologists, hematologists, oncologists, hospitals, and laboratories seeking comprehensive genomic profiling services to improve cancer diagnosis, treatment planning, and patient outcomes.
Features
- Comprehensive genomic profiling of both solid tumors and hematologic malignancies
- Next-generation sequencing (NGS) of DNA and RNA for a more complete molecular analysis
- Liquid biopsy options using cell-free DNA (cfDNA) and cell-free RNA (cfRNA) as a non-invasive alternative to tissue biopsies
- Detection of clinically relevant genes, including tumor mutation burden (TMB), MSI, HRD, fusions/translocations, copy number variations, amplifications, and deletions
- RNA sequencing capabilities that extend beyond fusion detection to include alternative splicing, gene expression, and prediction
- AI-powered informatics tools for rapid interpretation of complex genomic data sets
- Comprehensive reporting with clinical relevance for diagnosis, therapy, prognosis, heterogeneity, and potential clinical trials
- Fast turnaround times, with results available in 7 days for DNA tests and a maximum of 10 days for RNA tests